Illumina Inc (ILMN) — Analysis Summary
Illumina Inc (ILMN) has a market cap of $32.55B with year-over-year revenue growth of -0.7%. Net margin stands at 19.6%. The stock trades at a P/E ratio of 39.5.
Key Takeaways
- Revenue changed -0.7% year-over-year
- Net margin of 19.6%
- P/E ratio of 39.5
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, ILMN posted revenue growth of -0.7% and trades at a P/E of 39.5.
Illumina Inc (ILMN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
8,650
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.